In subjects with latent MM who were at risk of evolution to active myeloma, therapy with IL-1 inhibitors reduced the myeloma growth and CRP concentrations in those who responded, with a chronic disease state and an improved PFS [37]. This evidence concerns the gene IL1A and Miyoshi myopathy.